The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

Advisers are of course well placed to help people living with dementia and their families navigate a wide range of issues ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million. Vigil shares were trading around $8. The stock was up 36% on the ...

EXCLUSIVE: Chris Snell is urging anyone who notices these symptoms in a loved one to help them get checked for dementia.

A former project manager whose life was turned upside after developing Alzheimer's in his 40s is aiming to help others in his ...